We can identify four groups of potential partners both from the EU or outside the EU to whom we can help to gain specific benefits according to their nature and the place of origin.
Stem Cell and Regenerative Medicine companies from non EU countries (mostly USA and Canada) may have an interest for our offer basically for the cost effectiveness. Additional benefits:
Biotech companies from both EU and not EU countries, which are not specializing in Stem Cells and Regenerative Medicine may have an interest to our offer because:
CRO Companies have a potential of cooperation with us, using our expertise and infrastructure for common benefit:
Public Institutions and Research Centres aiming to conduct clinical trials in the domains of SC and RM they have an interest in exploring our proposal because:
Additionally, Institutions from non-EU countries can have: